Reader-Supported · Editorially Reviewed
§ Medication Guide

Wegovy Pill (Oral Semaglutide), Where to Get It Online in 2026

Compare verified wegovy pill online offers and published billing terms. Review the exact medication and commitment before enrolling.

1 study cited
1 Verified OffersIndependent Review

We may earn a commission through provider links. Matching affiliate offers and editorial priorities affect inclusion and suggested order in commercial guides. Scores are not clinical endorsements. Disclosure · Methodology

On December 22, 2025, the FDA approved Novo Nordisk's oral Wegovy (semaglutide 25 mg tablets) for chronic weight management, the first oral GLP-1 ever approved for an obesity indication in the US. This is a different product from Rybelsus, which has been on the market since 2019 but tops out at 14 mg and is approved only for type 2 diabetes. The pivotal OASIS 4 trial reported −16.6% mean body-weight loss at 64 weeks in adherent participants on the 25 mg dose: figures that put it on roughly the same efficacy plane as injectable Wegovy 2.4 mg without a head-to-head trial to confirm parity. As of writing, FuturHealth is the only consumer telehealth platform we have verified is actively dispensing the Wegovy pill at scale.

What It Is

Semaglutide 25 mg in oral tablet form, formulated with the SNAC absorption enhancer (sodium N-(8-[2-hydroxybenzoyl]amino)caprylate), the same delivery technology used in Rybelsus. The 25 mg obesity-indicated dose is roughly 1.8× the highest Rybelsus diabetes dose. Mechanistically identical to injectable Wegovy: a long-acting GLP-1 receptor agonist that slows gastric emptying, increases satiety, and reduces caloric intake. The differentiator is route, not molecule.

Who It's For

Adults with BMI ≥30, or ≥27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidaemia, OSA), who prefer a daily oral tablet to a weekly injection. The tablet form is most useful for needle-averse patients, frequent travellers who don't want to manage refrigerated pens, and patients who already take other once-daily morning medications and can absorb the fasted-window protocol into an existing routine.

What To Expect

Titration follows a four-step, ~16-week schedule: 1.5 mg (days 1–30) → 4 mg (days 31–60) → 9 mg (days 61–90) → 25 mg maintenance (day 91+), escalating roughly every 30 days if tolerated. The fasted-window protocol is strict: the tablet must be taken on an empty stomach with no more than 4 oz of plain water, at least 30 minutes before eating, drinking anything other than water, or taking any other oral medication. Coffee, supplements, and most other oral meds break the absorption window.

Verified Oral GLP-1 Pill Offers

1 verified
01
FuturHealth logo

FuturHealth

GLP-1 Weight LossFrom $198 – $395/mo
FDA-approved access
Best forGLP-1 paired with nutrition and fitness coaching

GLP-1 weight-loss platform combined with personalised nutrition and fitness coaching.

WegovyZepboundOzempicMounjarocompounded semaglutideoral glp-1 pills
Pros
Coaching layer included in the subscription
Wide brand-name GLP-1 access
Cons
Premium entry price
Coaching only matters if you actually use it
Editor Score4.0
Cost
3.7
Experience
4.4
Trust
4.2
Wegovy Pill at FuturHealthRead full review →
§ Clinical Evidence

What the Studies Actually Show

The evidence below comes from the OASIS 4 trial (the pivotal study for the December 2025 FDA approval of oral semaglutide 25 mg for weight management) and the FDA prescribing information. OASIS 4 data are from the adherent-participant analysis presented at EASD 2025.

EndpointFinding
Mean weight change (OASIS 4)1Oral semaglutide 25 mg produced 13.6% mean weight loss at 64 weeks by the treatment-policy estimand, versus 2.2% with placebo
Population and study limits1OASIS 4 studied adults with overweight or obesity without diabetes. It was a placebo-controlled trial, not a direct comparison with injectable semaglutide or tirzepatide
Formulation limits1Results from the studied oral tablet regimen do not establish equivalent outcomes for compounded oral drops, sublingual preparations, or other formulations
§ FAQ

Frequently Asked Questions

Is the Wegovy pill the same as Rybelsus?

No, and it is not just a renamed Rybelsus. Both products contain semaglutide and use the SNAC absorption enhancer, but Rybelsus is approved only for type 2 diabetes and tops out at 14 mg/day. Wegovy tablets are approved specifically for chronic weight management and dose to 25 mg/day. The 25 mg strength was not previously available in any oral GLP-1 product, and the obesity indication is what unlocks the larger affected patient population.

Is the Wegovy pill as effective as the Wegovy injection?

On available data, broadly yes, but the comparison is indirect. OASIS 4 reported −16.6% mean body-weight loss at 64 weeks in adherent participants on 25 mg daily; STEP 1 reported −14.9% at 68 weeks on injectable 2.4 mg weekly. Different trials, different populations, different durations, no head-to-head RCT. Real-world results will hinge on adherence to the 30-minute fasted window, a much higher daily compliance burden than a weekly injection.

Which telehealth providers prescribe the Wegovy pill?

As of mid-2026, FuturHealth has the most accessible direct telehealth path, a flat $198/mo coaching subscription bundled with medication access. Novo Nordisk's NovoCare cash channel provides direct fulfilment for self-pay patients (~$149/mo for 1.5 mg and 4 mg starter doses; higher for the 25 mg maintenance), with retail dispensing through Costco Pharmacy, Amazon Pharmacy, and Walmart. Most major GLP-1 telehealth platforms (Ro, Hims, Henry, Eden) had not added oral Wegovy to their public formularies at the time of writing; expect that to change as supply normalises.

Will compounding pharmacies make oral semaglutide for weight loss?

They cannot legally do so for the obesity indication. Compounded GLP-1s have always relied on the FDA's drug-shortage exemption or the personalisation exception. Now that brand-name oral semaglutide for weight loss is FDA-approved and commercially available, neither pathway applies. Any platform marketing 'compounded oral Wegovy' or 'compounded oral semaglutide for weight loss' in 2026 is operating outside the FDA framework. Compounded oral dissolving semaglutide for diabetes off-label use is a separate regulatory question.

Does insurance cover the Wegovy pill?

Coverage tracks injectable Wegovy closely. Plans that cover Wegovy for obesity will generally extend to the tablet; plans that exclude obesity-indicated GLP-1s will exclude both. The NovoCare savings card can reduce commercial copays meaningfully. For uninsured patients, NovoCare cash-pay starts at $149/mo for the 1.5 mg and 4 mg titration doses (4 mg at promotional rate through August 2026), currently the cheapest legitimate route during the early dose-escalation phase.

Can I switch from injectable Wegovy to the tablet?

Yes, under clinician supervision. There is no published 1:1 dose conversion. Standard practice is to restart oral titration at a low dose (typically 4 mg) rather than jumping straight to 25 mg, even for patients who are stable on injectable 2.4 mg. The titration takes weeks, so the switch carries some weight-regain risk during the transition unless overlap is managed deliberately.

References — Clinical Studies
  1. OASIS 4 — NEJM 2025 · Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. OASIS 4: 64-week placebo-controlled trial; the treatment-policy estimand showed 13.6% mean weight loss.

RxNotebook is an editorial publication, not a medical practice. We are not affiliated with the cited studies; source material does not endorse the providers shown. This is general information, not medical advice.

§ Continue Reading